Long term treatment of psoriatic arthritis with infliximab

We read with great interest the article by Feletar et al. We were surprised by their findings of only a modest response to infliximab treatment in patients with treatment refractory psoriatic arthritis (PsA), as this seems to be in contrast with our observations.

Since 2001 nine patients with refractory PsA according to American College of Rheumatology criteria have been treated with infliximab at our division. All patients had active joint disease with a tender joint count (TJC) and a swollen joint count (SJC) of at least 6, with the exception of one patient (patient 3), whose cervical spine was affected. Quantitative assessment of skin involvement was not available. Table 1 shows further demographic data.

Seven patients received infliximab for more than 52 weeks, and five of those for more than 78 weeks. Clinical assessment, including TJC and SJC, performed by experienced rheumatologists, and laboratory tests (haematology, biochemistry, antinuclear antibodies (ANA), including subsets) was made routinely at each visit (fig 1). During the treatment period toxicity occurred on three occasions, including one labial herpes infection (patient 4), one leucopenia of 2.6×10⁹/l (patient 3), which led to the discontinuation of methotrexate, and one allergic reaction (patient 9). Patient 9 had to stop infliximab treatment permanently despite an excellent clinical response, whereas the other two patients received infliximab again after the adverse events resolved. Six of the nine patients became positive for ANA—titre 1/80 on at least two successive visits. No serum conversion of ANA subsets occurred and no lupus-like symptoms were seen.

Eight of the nine patients showed rapid improvement and a clinical response. Only 1 patient (patient 8) was unresponsive to the treatment regimen, which was stopped. At 52 weeks five patients met the PsA response criteria, four patients were in complete remission (patients 1, 3, 5, 6) of joint tenderness and swelling, one patient (patient

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Number or mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M/F)</td>
<td>4/5</td>
</tr>
<tr>
<td>Age (years)</td>
<td>41 (13)</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>10.5 (8.0)</td>
</tr>
<tr>
<td>DMARDs per patient (n)</td>
<td>3.6 (1.3)</td>
</tr>
<tr>
<td>Current DMARD</td>
<td>Methotrexate</td>
</tr>
<tr>
<td>Mean dosage (mg/week)</td>
<td>17.5</td>
</tr>
<tr>
<td>Tender joint count*</td>
<td>16.4 (8.6)</td>
</tr>
<tr>
<td>Swollen joint count</td>
<td>10.5 (3.8)</td>
</tr>
<tr>
<td>HLA-B27 positivity</td>
<td>3</td>
</tr>
</tbody>
</table>

*Total number of joints counted 68; †Total number of joints counted 66.
2) had an incomplete response. Patient 4 stopped infliximab treatment in week 49 for 10 weeks because of a labial herpes infection that was treated with acyclovir. Thereafter tumour necrosis factor blocking therapy was successfully restarted.

At 78 weeks 4/5 patients (patients 1, 3, 4, 5) were in complete remission. One patient (patient 2) who had an incomplete response with a 6 weeks' treatment interval showed complete remission after the interval was shortened to 4 weeks. Patient 1 who received his first infliximab dose at our division 16 weeks ago had been responding so well to the treatment that we stopped giving infliximab after his 16th infusion at the end of week 120. Because of disease exacerbation, treatment had to be restarted 26 weeks later and within a few days (data not shown) the patient regained complete remission.

These data, although only retrospectively obtained, suggest that infliximab is a valuable therapeutic tool for treating refractory PsA. So far, permanent discontinuation of treatment owing to toxicity or inefficacy has only been necessary for one of the nine patients.

One possible reason for the different outcome in the effect of infliximab on PsA in our patients and those of Feletar et al might be the severity of the joint disease in Feletar's patients. Fifteen out of 16 of their patients had mutilating arthritis, whereas this form of arthritis was not present in our group. To clarify this possibility, further studies with larger groups and well-defined joint disease are necessary.

Division of Rheumatology, Department of Internal Medicine, Medical University Graz, Austria

R I Brezinschek
Division of Haematology, Department of Internal Medicine, Medical University Graz, Austria

Correspondence to: Professor H-P Brezinschek, Division of Rheumatology/Department of Internal Medicine, Medical University Graz, Auenbruggerplatz 15 A-8036 Graz, Austria; hans-peter.brezinschek@meduni-graz.at

References


Author's reply

Yazdani-Biuki et al were surprised that our data on 16 patients with arthritis treated with infliximab demonstrated only a modest response. They contrast our data with data from nine patients with psoriatic arthritis (PsA) treated with infliximab in their centre. Although they mention nine patients, only seven were treated for more than 52 weeks. They claim that eight of the nine patients demonstrated rapid clinical response, but provided information on only five patients who demonstrated a PsA American College of Rheumatology response, four of whom are said to be in complete remission. It is not clear whether the other patients discontinued the drug, in which case their withdrawal rate would be 22.

This is in contrast with the results of our study, which demonstrated a high toxicity rate, and high level of discontinuation (6/16 or 38%). We had previously suggested that the difference between our study and others might reflect the severity of our patient group. The group treated by Yazdani-Biuki et al was demographically somewhat different from our group. There were more men in our study (12/16 vs 4/5), they were older (48 ± 14) and had longer disease duration (14 v 10.5). However, the same average number of disease-modifying antirheumatic drugs had been used in the two groups. Yazdani-Biuki et al did not provide information on damage in their patients. Our group included five patients with arthritis mutilans; however, all these patients had evidence of inflammatory arthritis. The other five patients may have had evidence of damage but did not demonstrate arthritis mutilans. Because we have previously shown that the presence of damage predisposes not only to progression of damage but also to early mortality in this patient group, we felt it was important to give these patients the best possible treatment.

We agree with Yazdani-Biuki et al that the difference between the results of our two studies may be related to the difference in disease severity between the two groups. However, the number of patients is too small to draw valid conclusions. It is important to gain more experience with anti-tumour necrosis factor agents both in randomised clinical trials and clinical observational studies, including a wide range of patients with PsA, so that the true level of response and toxicity can be identified.

D Gladman
Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, ECW 5-0348, 399 Bathurst St, Toronto, Ontario, Canada M5T 2S8

Correspondence to: Dr D Gladman; dafna.gladman@utoronto.ca

References


Rapid response

If you have a burning desire to respond to a paper published in the Annals of the Rheumatic Diseases, why not make use of our “rapid response” option. Log on to our website (www.annrheumdis.com), find the paper that interests you, and send your response via email by clicking on the “elteers” option in the box at the top right hand corner. Providing it isn't libellous or obscene, it will be posted within seven days. You can retrieve it by clicking on “read elteers” on our homepage.

The editor will decide as before whether also to publish it in a future paper issue.

D Gladman
Rheumatology Research Unit, Repatriation General Hospital, South Australia 5041, Australia

Correspondence to: Dr M D Smith; malcolm.smith@rgh.sa.gov.au

References

Authors’ reply

We thank Dr Smith for alerting readers and us to the existence of his excellent paper that came out after our study was done and during the preparation of our manuscript. Our study described asymptomatic subjects, a somewhat different group from that in Dr Smith’s study—namely, patients with unexplained knee pain with clinically and arthroscopically normal knee joints. It is fascinating that in this study arthroscopy could not detect moderate inflammation seen in some synovial fluids. Thus, some synovitis can be present even when examinations and gross arthroscopy are normal. Future studies of patients like ours and those of Smith et al would benefit from longer follow up. What was the final cause of the knee pain that led to the need for arthroscopy? Will the cellular pattern be consistent, resolving, or progressive in some patients? Do the infiltrates seen in some “normal subjects” have any prognostic significance?

It appears that our two studies1,2 with many similar findings reinforce the point, also noted before by Lindblad and Hedfors,3 that there may be more variability in synovial histology, inflammation, and biochemistry than many may have appreciated.

J A Singh, H R Schumacher
Minneapolis VA Medical Center, Minneapolis, USA

Correspondence to: Dr J A Singh; singh046@umn.edu

References


Low dose prednisolone for treatment of RA

We read with interest the report of the WOSERACT trial that compared the addition of 7 mg daily prednisolone or placebo to sulphasalazine in early rheumatoid arthritis (RA). A number of important aspects of the trial have been dealt with well; the sample size is adequate; appropriate attention has been paid to confounders; two separate and independent readers scored the radiographs; the 2 year trial was of adequate length; and the dataset yields of the data is satisfactory. Given these strengths, it is all the more disappointing that the results of the main outcome, radiographic damage, cannot be adequately interpreted as they are reported. Indeed, the validity of these results is open to serious doubt. We feel there is a real possibility of a type II statistical error (missing a true difference between treatment arms). There are two (possibly three) reasons for this. First, there is an absolute difference between the x ray scores of the two readers of about 40 Sharp points. This raises strong doubts over the proficiency of either or both readers. In early RA Sharp scores are typically very low, the best patients scoring 0 and only a few with higher scores. Scores of 80, let alone 159, after one year of RA are without precedent in the literature, and even the baseline medians of 6 and 8 recorded for the conservative reader are quite high. In contrast with the authors, we cannot be “rassured” by their assertion that “the change in x ray score was consistent between the two readers”1: these data are simply not provided in the report. All we have is an unsatisfactory correlation of absolute scores between readers in most of these trials the intraclass correlation coefficient (the recommended and more severe test of reliability between readers) exceeds 0.9, and the comparison between readers of different centres and end points in the two study groups. Unfortunately, the difference between medians at baseline and end point is not the same as the median change.

Secondly, most trials choose two readers who read either with sequence known or unknown (the jury is still out on which is the preferred method), and report the mean of these two readings. This report has two readers, each of whom uses a different one of these options, and this makes it impossible to pool the results. Also, even with sequence unknown, films should be read as sets (all films belonging to a patient assessed simultaneously), not totally at random. Reading totally at random strongly decreases the signal to noise ratio.1 Which method did the “random” reader apply exactly?

A third concern is with the analysis, although this may only be a question of the way in which the data are presented. Although the authors state that the main outcome measure is the change in radiographic damage, they only report medians and ranges of the absolute scores in the groups. From our reading of the report, we fear the analysis has (statistically) compared the distributions of these absolute scores rather than their changes.

This is an important study, and has the potential to add valuable information to our understanding of the best way to treat RA, but in its present form the radiographic results are more likely to cloud the issues than clarify them. We suggest that the radiographs are made available to be re-read by two new, experienced readers, with either the sequence known or unknown to both. We also suggest that the authors should present the median, range, etc, of the changes in each group, and the test of the difference between these. (If they have a skewed distribution, then either transformation before parametric analysis or the use of non-parametric methods would be the best way to compare the groups.)

There are other difficulties with the study, although these are less important than the essential concerns noted above. For example, we are baffled by the statement in the introduction that the COBRA combination “showed radiological advantage over sulphasalazine alone but the study was not powered to detect differences in x ray change”. In fact, the differences in x ray change were among the key findings of the COBRA study, and have since been shown to increase over time.2 So the study was not only adequately powered but also showed an unexpectedly large effect.

The authors diminish the value of the report by inappropriate interpretation of their secondary data, especially on the adverse effects. In the discussion they comment, “While observed toxicity from corticosteroids in terms of hypertension, weight gain, and osteoporosis could be reduced by active assessment and prompt intervention, there is no room for complacency”. However, in their results section they report that, “Low dose aspirin and treatment for ischaemic heart disease remained similar, whereas the use of antihypertensive agents increased in both groups, as did prescription of lipid lowering agents. The use of any treatment for osteoporosis also increased in both groups” in fact there was no difference between the groups and thus there was no observed toxicity from glucocorticoids in their study. Further, the authors make no comment on their observation that more patients in the placebo group than in the glucocorticoid group stopped sulphasalazine treatment owing to side effects. In relation to weight gain, inappropriate attention to within-group changes leads the authors to conclude that body weight “increased significantly” in the glucocorticoid group (median gain 4 kg), with only a “ borderline increase” in the placebo group (median gain 3 kg). Body mass index is handled in the same way. However, the only really relevant comparisons, those between groups, do not even show a trend to significance (all p values >0.10). As with the radiographic findings, the presentation of the table suggests end point results were compared rather than change scores.

Our interpretation of the clinical results contradicts that of the investigators, and we conclude that the effects on symptoms are in line with previous reports of limited and temporary advantages for disease activity, blunting of sulphasalazine toxicity, and extremely limited side effects when appropriate caution is applied. It is not possible to assess adequately the main results on x ray progression, which are at variance with several previously published studies,3,4 and we urge the authors to allow a second read of the radiographs so that their important dataset can be added to the existing evidence.

J Kirwan
University of Bristol Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol BS2 BWV, UK

M Boers
Department of Clinical Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, The Netherlands

Correspondence to: Dr J Kirwan; john.kirwan@bristol.ac.uk

References


Authors’ reply

We agree with John Kirwan and Maarten Boers that the assessment of radiographic damage in the WOSERACT study is of importance. The method of reading radiographs has evolved since this study was planned in 1995.6 Because we consider that “the jury is out”, on the optimal way to read radiographs in studies the films were read (a) at random by one reader and (b) in sequence by the other reader, and the same conclusion was reached. This strengthens rather than weakens the case for a true result.

The study of Paulus et al.,7 in which there was no beneficial effect on radiographic outcome in 197 patients with rheumatoid arthritis (RA), supports the WOSERACT study findings. It was unfortunate that in the Arthritis and Rheumatism Council (ARC) low dose corticosteroid study the two groups were not well matched at the outset, making interpretation of the true effect of prednisolone at 2 years and of the subsequent report difficult.8

The COBRA study used a high initial corticosteroid dose and the effects contributing to prompt disease control were multifactorial. It is similarly not possible to extrapolate from the study of van Everdingen et al.9 because they used a protocol of steroid without initial disease modifying antirheumatic drug, which is not a practice supported by current guidelines on RA management.

There was considerable discussion among the WOSERACT investigators about the approach to glucocorticoid side effects. It was decided that management of these would be the responsibility of the individual consultant, who remained unaware of the treatment assignment. For this reason there is likely to be a great deal of background noise. This issue was not a primary end point of our study but information is available from other studies.10 We do agree that the blunting of sulfasalazine toxicity in the active group is of interest, although it would be inappropriate to advocate the use of prednisolone for this reason alone.

At a time when multiple treatments are increasingly used in early RA it is vital to be certain what contribution, if any, oral corticosteroids might make. The fact that both the ARC study and ours showed no sustained clinical benefit, makes x ray interpretation all the more important.

Thus we suggest that with John Kirwan and Marten Boers an approach is made to the ARC (the original sponsors of the 1995 study), or to EULAR, for sufficient funding to allow independent readers and statisticians to evaluate all appropriate datasets. This would allow films from relevant studies to be copied and made available as a central repository for future study. The films from the study of Rau et al. would also be useful for this initiative.

H Capell, J Hunter, R Madhok, E Morrison, J Larkin on behalf of the WOSERACT group

Centre for Rheumatic Diseases, Glasgow, UK

Correspondence to: Dr H A Capell; hilary.capell@northglasgow.scot.nhs.uk

References


FORTHCOMING EVENTS

4th International Congress on Autoimmunity

3–7 November, 2004, Budapest, Hungary

Contact: 4th International Congress on Autoimmunity, Kenes International—Global Congress Organisers and Association Management Services, 17 rue du Cendrier, PO Box 1726, CH-1211 Geneva 1, Switzerland
Tel: +41 22 908 0488
Fax: +41 22 732 2850
Email: autoimm04@kenes.com
Website: www.kenes.com/autoimm2004

ARC Epidemiology Unit Golden Jubilee Symposium

4–5 November 2004; Manchester, UK
Rheumatic disease epidemiology: yesterday, today, and tomorrow
Email: gillian.amroon@man.ac.uk
Website: www.arc.man.ac.uk

17th Congres Francais de Rhumatologie

15–17 November 2004; Paris, France
Contact: Catherine Rollat
Tel: +33 01 42 50 00 18
Fax: +33 01 42 50 10 68
Email: c.rollat.sf@wanadoo.fr
Website: www.rhumatologie.asso.fr

8th EULAR Postgraduate Course in Rheumatology

28 November–3 December 2004; Prague, Czech Republic
Contact: EULAR Secretariat, Witkoninerstrasse 15, CH 8032 Zurich, Switzerland
Tel: +41 1 383 96 90
Fax: +41 1 383 98 10
Email: secretariat@eular.org
Website: www.eular.org

Osteoarthritis Research Society International

2–5 December 2004; Chicago, USA
Contact: 17 000 Commerce Parkway, Suite C, Mt Laurel, NJ 08054, USA
Email: oarsi@oarsi.org
Website: www.oarsi.org

VIIIth European Lupus Meeting

3–5 March 2005; Royal College of Physicians, London, UK
Contact: Julia Kermode, Conference organiser of the British Society of Rheumatology
Email: Julia@Rheumatology.org.uk

International Society for the Study of the Lumbar Spine Instructional Course

27, 28 March 2005; Nairobi, Kenya
Controversies in diagnosis and treatment of lumbar spinal conditions
Contact: Shirley Fitzgerald, 2075 Bayview Avenue, Room 5G323, Toronto, Ontario, Canada M3B 3M5
Tel: 416 480 4833
Fax: 416 480 6055
Email: shirley.fitzgerald@sw.ca

BSR Annual Meeting 2005

19–22 April 2005; ICC, Birmingham, UK
Joint meeting with the German Society for Rheumatology
Abstract submission deadline 15 November 2004
Contact: BSR, 41 Eagle Street, London WC1R 4TL
Tel: +44 (0) 20 7242 3313
Fax: +44 (0) 20 7242 3277

EULAR 2005

8–11 June 2005; Vienna, Austria
Contact: EULAR Secretariat
Tel: +43 1 383 96 90
Fax: +43 1 383 98 10
Email: secretariat@eular.org
Website: www.eular.org/eular2005

Future EULAR congress

21–24 June 2006; EULAR 2006, Amsterdam, The Netherlands
Long term treatment of psoriatic arthritis with infliximab


Ann Rheum Dis 2004 63: 1531-1532

Updated information and services can be found at:
http://ard.bmj.com/content/63/11/1531

These include:

References
This article cites 4 articles, 1 of which you can access for free at:
http://ard.bmj.com/content/63/11/1531#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/